Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Kidney Transplantation in Highly Sensitized Patients”

Showing 4 of 0 results

Large-scale testing (Phase 3)Study completedNCT04935177
What this trial is testing

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

Who this might be right for
Kidney Transplantation in Highly Sensitized Patients
Hansa Biopharma AB 64
Testing effectiveness (Phase 2)Study completedNCT01594424
What this trial is testing

A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

Who this might be right for
End Stage Renal Disease (ESRD)
Cedars-Sinai Medical Center 10
Large-scale testing (Phase 3)Study completedNCT00000935
What this trial is testing

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

Who this might be right for
End-Stage Renal DiseaseKidney Transplantation
National Institute of Allergy and Infectious Diseases (NIAID) 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05092347
What this trial is testing

Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

Who this might be right for
Chronic Kidney Disease (CKD)
Regeneron Pharmaceuticals 43

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation